TNXP Stock Analysis: Buy, Sell, or Hold?
TNXP - Tonix Pharmaceuticals Holding Corp.
$12.03
0.06 (0.54%)
▲
5d:
+3.4%
30d:
-5.83%
90d:
-21.61%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When TNXP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TNXP shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TNXP shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: TNXP is currently trading at $12.03, which is considered fair relative to its 30-day fair value range of $11.23 to $13.17.
Technical Outlook: Technically, TNXP is in a strong downtrend. Immediate support is located at $10.87, while resistance sits at $13.04.
Market Sentiment: TNXP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.25 (+286.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TNXP is in a strong downtrend. Immediate support is located at $10.87, while resistance sits at $13.04.
Market Sentiment: TNXP has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.25 (+286.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.23 -
$13.17
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 286.7% below Wall St target ($46.25)
Trading Range Analysis
30-Day Trading Range
$11.23 -
$13.17
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$1.55
(12.9%)
Support & Resistance Levels
Support Level
$10.87
Resistance Level
$13.04
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.53
Wall Street Target
$46.25
(+286.7%)
Revenue Growth (YoY)
183.2%
Share & Embed Analysis
Last updated: June 24, 2026 10:12 AM ET
Data refreshes hourly during market hours. Next update: 11:12 AM
Data refreshes hourly during market hours. Next update: 11:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNXP showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Seth Lederman
BUY
15000 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
